Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer

INTRODUCTION: Mutations affecting p53 or its upstream activator Chk2 are associated with resistance to DNA-damaging chemotherapy in breast cancer. ATM (Ataxia Telangiectasia Mutated protein) is the key activator of p53 and Chk2 in response to genotoxic stress. Here, we sought to evaluate ATM's...

Descripción completa

Detalles Bibliográficos
Autores principales: Knappskog, Stian, Chrisanthar, Ranjan, Løkkevik, Erik, Anker, Gun, Østenstad, Bjørn, Lundgren, Steinar, Risberg, Terje, Mjaaland, Ingvil, Leirvaag, Beryl, Miletic, Hrvoje, Lønning, Per E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446381/
https://www.ncbi.nlm.nih.gov/pubmed/22420423
http://dx.doi.org/10.1186/bcr3147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446381/
https://www.ncbi.nlm.nih.gov/pubmed/22420423
http://dx.doi.org/10.1186/bcr3147

Ejemplares similares